Calcium supplementation and its effect on bone loss in renal transplant recipients.

Phase 4

Completed

• Conditions: Bone loss in renal transplant recipients.; Hyperparathyroidism in renal transplant recipients.; Renal and Urogenital - Kidney disease; Metabolic and Endocrine - Metabolic disorders; Musculoskeletal - Osteoporosis

• Registration Number: ACTRN12609000250235
• Lead Sponsor: Dr Patrick T Coates

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Previous renal transplant over 1 year ago.
Stable renal function (Creatinine < 150) Standard immunosuppression regime (Tacrolimus, Mycophenolate Mofetil and Prednisolone).
Able to give informed consent.
Able to attend 3 sessions held over 1 week.

Exclusion Criteria

Preexisting hypercalcemia (Ca > 2.55 mmol/L), severe hyperparathyroidism (PTH > 50 pmol/L) or severe vitamin D insufficiency (serum 25-hydoxy vitamin D < 15 ng/mL).
Previous parathyroidectomy.
Concurrent use of bisphosphonates, Vitamin D analogues, lithium, phenytoin, carbamazepine, hormone replacement therapy, thiazide diuretics.
Participation in a concurrent study.
Pre-menopausal women (due to low level radiation exposure).

Study & Design

• Study Type: Interventional
• Study Design: Not specified